Trial · NCT02993302
Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
NCT02993302, Phase 2, Completed, Dr Cipto Mangunkusumo General Hospital; results first posted 2020-02-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients. Trials, record NCT02993302. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02993302
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
- NCT number
- NCT02993302
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 25 participants, actual
- Lead sponsor
- Dr Cipto Mangunkusumo General Hospital
- Conditions
- Graves Disease
- Interventions
- 1α-D3, Placebos
- First posted
- 2016-12-15
- Last updated
- 2020-03-04
- Results first posted
- 2020-02-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CD80 Level | 1 year | Dendritic cells maturation levels were measured by the CD80 (cluster of differentiation 80) |
| Primary | CD206 Level | 1 year | Dendritic cells maturation levels were measured by the CD206 |
| Primary | IL-12/IL-10 Ratio | 1 year | Dendritic cells maturation levels were measured by the IL-12 (interleukin-12)/IL-10 ratio |
| Primary | fT4 Levels | 1 year | fT4 (free thyroxine) |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | CD80 Level | 1 year | nM | MEDIAN | |
| PRIMARY | CD206 Level | 1 year | nM | MEAN | |
| PRIMARY | IL-12/IL-10 Ratio | 1 year | ratio | MEDIAN | |
| PRIMARY | fT4 Levels | 1 year | ng/dL | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| CD80 Level | PTU + Oral 1α-D3 | 45.60 | Full Range 31.20 to 139.36 | nM | |
| CD80 Level | PTU + Placebos | 54.51 | Full Range 39.47 to 69.55 | nM | |
| CD206 Level | PTU + Oral 1α-D3 | 54.08 | Standard Deviation 23.46 | nM | |
| CD206 Level | PTU + Placebos | 53.42 | Standard Deviation 13.72 | nM | |
| IL-12/IL-10 Ratio | PTU + Oral 1α-D3 | 0.49 | Full Range 0.04 to 8.01 | ratio | |
| IL-12/IL-10 Ratio | PTU + Placebos | 0.21 | Full Range 0.03 to 3.40 | ratio | |
| fT4 Levels | PTU + Oral 1α-D3 | 2.65 | Standard Deviation 2.06 | ng/dL | |
| fT4 Levels | PTU + Placebos | 2.09 | Standard Deviation 1.19 | ng/dL |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PTU + Oral 1α-D3 | 13 | |
| Overall Study | STARTED | PTU + Placebos | 12 | |
| Overall Study | COMPLETED | PTU + Oral 1α-D3 | 13 | |
| Overall Study | COMPLETED | PTU + Placebos | 12 | |
| Overall Study | NOT COMPLETED | PTU + Oral 1α-D3 | 0 | |
| Overall Study | NOT COMPLETED | PTU + Placebos | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | PTU + Oral 1α-D3 | 0 | 13 |
| Total, all-cause mortality | PTU + Placebos | 0 | 12 |
| Total, other adverse events | PTU + Oral 1α-D3 | 0 | 13 |
| Total, other adverse events | PTU + Placebos | 0 | 12 |
| Total, serious adverse events | PTU + Oral 1α-D3 | 0 | 13 |
| Total, serious adverse events | PTU + Placebos | 0 | 12 |
Source ClinicalTrials.gov
Papers24
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| PTU + Oral 1α-D3 vs PTU + Placebos: deaths from any cause | Trial comparisons |
| PTU + Oral 1α-D3 vs PTU + Placebos: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02993302
GET https://conductscience.org/api/trials/v1/NCT02993302/papers?page=2